A Multi-Center, Open-Label, Randomized Controlled Trial to Evaluate the Efficacy of Convalescent Plasma Therapy for Coronavirus Disease 2019: A Trial Protocol (COVIPLA-RCT)

Background: Coronavirus disease 2019 is a global public health concern. As of December 2020, the therapeutic agents approved for coronavirus disease 2019 in Japan were limited to two drugs: remdesivir, an antiviral drug, granted a Special Approval for Emergency on 7 May 2020, and dexamethasone, whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Noriko, Saito, Sho, Terada-Hirashima, Junko, Mikami, Ayako, Uemura, Yukari, Kutsuna, Satoshi, Nomoto, Hidetoshi, Fujisawa, Kyoko, Nagashima, Maki, Terada, Mari, Ashida, Shinobu, Morioka, Shinichiro, Satake, Masahiro, Hangaishi, Akira, Togano, Tomiteru, Shiratori, Katsuyuki, Takamatsu, Yuki, Maeda, Kenji, Ohmagari, Norio, Sugiura, Wataru, Mitsuya, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225318/
https://www.ncbi.nlm.nih.gov/pubmed/35743887
http://dx.doi.org/10.3390/life12060856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225318/
https://www.ncbi.nlm.nih.gov/pubmed/35743887
http://dx.doi.org/10.3390/life12060856

Ejemplares similares